An interventional study of Ferrous Fumarate and Placebo in Iron-deficiency, Microbial Colonization and Anemia, sponsored by South Australian Health and Medical Research Institute. Completed at 1 site in Australia. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.
Sponsored by South Australian Health and Medical Research Institute · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency — 2 open to participants now, 2 under way, none of them phase 3. ferrous fumarate · Anemia, Iron-Deficiency.
Among the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, this one is the 6th largest by enrollment, is the only one that started in 2021, is one of 6 with no phase, and was the 8th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →2 of the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency are open now, in 2 countries. Recruiting first, the newest first:
Phramongkutklao College of Medicine and Hospital · Sites in Thailand
Ages 20+
Dr. Anil K. Gupta Medicine Professional Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
ferrous fumarate: first FDA approval 1978 (NORMINEST FE). What it is approved for, and how studies give it, is on its page →
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 1 · Phase 4 2
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is below the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 74 across the 12 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
South Australian Health and Medical Research Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
South Australian Health and Medical Research Institute has 1 study filed under Anemia, Iron-Deficiency — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing ferrous fumarate in Anemia, Iron-Deficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this randomised controlled trial the investigators will determine whether taking iron supplements compared to placebo for 21 days alters the bacteria (microbiome) in the large intestine of non-pregnant female participants.
BACKGROUND: Many women take iron-containing supplements during pregnancy. Indeed, the World Health Organization recommends that all pregnant women in low-income countries take an iron supplement containing 60 mg/day of elemental iron to reduce iron deficiency and iron-deficiency anaemia. However, oral iron has poor bioavailability, less than 10% absorbed with the remainder passing into the large intestine unbound, potentially providing a competitive advantage to iron-dependent opportunistic pathogens in the large intestine.
In a large randomized control trial in children, iron supplementation was shown to promote the growth of pathogenic species (E. coli, S. aureus, and L. monocytogenes) and inhibited the growth of commensal species (Lactobacillus and Bifidobacterium). These pathogens are associated with enteric infections, while the commensals act on the host's immune system to prevent colonization and invasion by pathogens.
It is NOT known if iron supplementation during pregnancy impacts the maternal and infant microbiome and, by extension, how this affects the neonatal risk of infection and immune dysregulation. Vertical transmission of the maternal microbiome to the newborn is a major determinant of infant health. If maternal iron supplementation affects the infant's health, strategies would be required to mitigate this risk.
The investigators require preliminary data to show how oral iron supplementation alters the intestinal microbiome in women. The Investigators will recruit non-pregnant female participants as there is no risk of vertical transmission to an infant in non-pregnant women. The investigators will conduct the study in Australia because there is not a natural abundance of pathogens that could potentially cause harm to the women. Nevertheless, the investigators would expect a shift in the microbiome from non-iron to iron, requiring bacterial species to return to baseline after women stop taking the iron.
HYPOTHESIS: Daily iron supplementation versus placebo for 21 days will alter the stool microbiome composition compared to placebo in non-pregnant female participants of reproductive age.
METHODS: 80 female participants (18-45 y) will be randomized to receive capsules containing iron (65.7 mg of elemental iron as ferrous fumarate) or placebo to take daily for 21 days. Stool samples will be collected at baseline, 21 days, and 42 days (washout).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
65.7 mg of iron as ferrous fumarate
Dietary Supplement: Ferrous Fumarate
0 mg of iron
Dietary Supplement: Placebo
Gelatin capsule containing 200 mg ferrous fumarate and microcrystalline cellulose
Also known as: Iron Fumarate, ferro-tab
Gelatin capsule containing microcrystalline cellulose
Also known as: Control
Weighted UniFrac dissimilarity score
Measure of microbiota beta-diversity
Time frame: 21 days
Bray-Curtis dissimilarity score
Measure of microbiota beta-diversity
Time frame: 21 days
Shannon Wiener Diversity
Microbiota alpha-diversity score with adjustment for baseline levels
Time frame: 21 days
Faith's phylogenetic diversity
Microbiota alpha-diversity score with adjustment for baseline levels
Time frame: 21 days
Taxonomic richness
Microbiota alpha-diversity score with adjustment for baseline levels
Time frame: 21 days
Relative abundance of core bacterial taxa
Relative abundance of taxa present in \>40% of baseline samples, with adjustment for baseline levels
Time frame: 21 days
Weighted UniFrac dissimilarity score
Measure of microbiota beta-diversity
Time frame: 42 days (washout)
Shannon-Wiener diversity
Microbiota alpha-diversity score with adjustment for baseline levels
Time frame: 42 days (washout)
Bray-Curtis dissimilarity score
Measure of microbiota beta-diversity
Time frame: 42 days (washout)
Faith's phylogenetic diversity
Microbiota alpha-diversity score with adjustment for baseline levels
Time frame: 42 days (washout)
Taxonomic richness
Microbiota alpha-diversity score with adjustment for baseline levels
Time frame: 42 days (washout)
Relative abundance of core bacterial taxa
Relative abundance of taxa present in \>40% of baseline samples, with adjustment for baseline levels
Time frame: 42 days (washout)
Plan to share: Yes — Outlined below
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Following final data analysis and primary publication
Access criteria: Access to study data may be granted, upon review and approval of the Institutional Review Board, investigators, in accordance with South Australian Health and Medical Research Institute Women and Kids 'Guidelines and Agreement for the use of materials in an ancillary study associated with original clinical trials or cohort studies.
No publications or documents are linked to this record.
Ran from Aug 2021 to primary completion in Nov 2021, 2 months.
Of 133 non-industry interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 2 months is below that.
Counting every sponsor, half of 142 studies reached it within 11 months; a quarter within 3 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferrous fumarate
South Australian Health and Medical Research Institute